SPECIALIZED EXPERTISE
IMPACTFUL INVESTMENTS
A fund accelerating breakthroughs in blood and cellular
therapies and supporting technologies
NYBC Ventures elevates investment performance by leveraging New York Blood Center’s unparalleled expertise in blood and cellular therapies.
AREAS OF FOCUS
HEMATOLOGY
TRANSFUSION
MEDICINE
CELL THERAPY
INFECTIOUS
DISEASE
INVESTMENT TEAM
A dedicated team of professional investors driven by a passion for supporting innovation, visionary founders, and exceptional companies.
CHRISTOPHER D.
HILLYER MD
GENERAL PARTNER
MANAGER
JAY MOHR
GENERAL PARTNER
MANAGER
MEG WOOD, MPH
MANAGING DIRECTOR
KUAN YU
SR ANALYST
BOARD OF MANAGERS
JOHN ROSENTHAL
CHAIR
JUNG CHOI
MANAGER
CRISTINA CSIMMA
MANAGER
DAVID KABAKOFF
MANAGER
PORTFOLIO
Our investment strategy targets promising early to mid stage innovations in blood and cellular therapies and related technologies. We support therapeutics, devices, and other breakthrough solutions that address key challenges in our fields of interest.
ABOUT
NYBC Ventures, launched by New York Blood Center Enterprises (NYBCe) with a $50M commitment, drives innovation in blood-related fields, cellular therapies, and related technologies to improve patient lives. For over 60 years, New York Blood Center has provided top-quality blood products and transfusion services. Its research arm, the Lindsley F. Kimball Research Institute (LFKRI), is one of the world’s preeminent blood research organizations conducting foundational, epidemiologic, and clinical research. Comprehensive Cell Solutions (CCS), is a cell and gene therapy-focused development and manufacturing organization that provides critical capacity to an underserved population of early-stage developers, as well as expertise and strategic footprint for hospital treatment centers and pharmaceuticals organizations.
